NAUT NAUTILUS BIOTECHNOLOGY INC

Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award

Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award

Society award recognizes Dr. Mallick’s decades of innovative leadership and science advancing the field of computational proteomics

SEATTLE, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced Nautilus co-founder and Chief Scientist Parag Mallick, Ph.D., was selected as the 2024 recipient of the Gilbert S. Omenn Computational Proteomics Award presented by the US Human Proteome Organization (US HUPO).

The award Dr. Mallick’s career achievements and contributions to bioinformatics analyses and computational methods widely used by the proteomics community.

“Developments in computational proteomics enable researchers globally to advance biomedicine,” said Dr. Mallick. “I am extremely grateful to receive the Computational Proteomics Award from US HUPO. A huge thank you is due to my many students and collaborators who have been instrumental partners.”

Dr. Mallick’s contributions began during his post-doctoral studies with Dr. Ruedi Aebersold at the Institute for Systems Biology where he, in collaboration with researchers from the Küster lab, first defined proteotypic peptides and elaborated their potential utility in quantitative proteomics experiments. He additionally contributed to some of the earliest initiatives to integrate large-scale proteomics data with genomics data.

Dr. Mallick’s lab at Stanford University (previously, at Cedars-Sinai Medical Center, UCLA, and USC) led the development of the ProteoWizard Toolkit, a modular and expandable collection of open-source, cross-platform tools and software development frameworks. From its initial conception, ProteoWizard aimed to help reduce the barriers to developing and deploying robust, easy-to-use proteomics data analysis tools that could operate transparently on any data from any instrument. Working closely with research labs around the world, particularly the MacCoss and Tabb labs, and all the major instrument vendors, ProteoWizard became the reference implementation of the community data standards that today ubiquitously enable data sharing across the field and the first tool that could read all major vendor formats. Outside of his work on ProteoWizard, Dr. Mallick and his lab have also contributed to the discovery of cancer biomarkers and mechanisms, novel methods for multi-omic data integration, and advances in machine learning.

“Working side-by-side with Parag since we founded Nautilus, I’ve witnessed firsthand his incredible personal commitment and contributions to computational proteomics,” said Sujal Patel, CEO of Nautilus. “His work is key to unlocking the potential of the proteome and delivering breakthroughs across fundamental science.”

Dr. Mallick will formally receive the award and present a lecture at the 20th Annual US HUPO conference taking place March 9-13, 2024 in Portland, Oregon.

About Nautilus Biotechnology, Inc.

With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit .

Media Contact

Investor Contact

A photo accompanying this announcement is available at



EN
30/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NAUTILUS BIOTECHNOLOGY INC

 PRESS RELEASE

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Fin...

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights Continued progress was made in processing and analyzing Tau proteoform samples from collaborators to support platform validation and expanding scientific publications. Externally generated Tau da...

 PRESS RELEASE

Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molec...

Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026 • Revealed core proteomics instrument during US HUPO 2026 following successful field evaluation at the Buck Institute for Research on Aging • Commercial launch expected to initiate in late 2026, marking a major milestone for next-generation proteomics • Researchers invited to apply to the Early Access Program to use Iterative Mapping, Nautilus’ technology designed to measure billions of intact protein molecules, ahead of broader commercial availability Nautilus Voyager™ Platform ...

 PRESS RELEASE

Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Heal...

Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 46th Annual Health Care Conference. Nautilus’ management is scheduled to participate in a fireside chat on Monday, March 2, 2026, at 10:30 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the ...

 PRESS RELEASE

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 F...

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year 2025 before market open on Thursday, February 26, 2026. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business development...

 PRESS RELEASE

Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate wi...

Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease • Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’ development of a single-molecule assay for measuring alpha-synuclein proteoforms is its latest application of Iterative Mapping method to uncover new biological insights• Weill Cornell Medicine-Qatar’s deep chemical biology and neurology expertise and field-leading protein stand...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch